Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 52

Results For "gene"

2919 News Found

Bayer’s pharma growth strategy progressing well as pipeline advances
News | January 15, 2025

Bayer’s pharma growth strategy progressing well as pipeline advances

Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid


Apotex acquires US rights to PROVIGIL and NUVIGIL
News | January 13, 2025

Apotex acquires US rights to PROVIGIL and NUVIGIL

PROVIGIL and NUVIGIL are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy


Zaynich achieves over 97% efficacy in clinical study for meropenem-resistant gram-negative pathogens
Diagnostic Center | January 13, 2025

Zaynich achieves over 97% efficacy in clinical study for meropenem-resistant gram-negative pathogens

The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure


Genome India Project marks a defining moment for country's biotechnology landscape: Modi
Policy | January 11, 2025

Genome India Project marks a defining moment for country's biotechnology landscape: Modi

Modi remarked that more than 20 illustrious research institutions such as IISc, IITs, CSIR and DBT-BRIC have played a major role in this research


JP Nadda inaugurates new Library and Informatics Centre at LGB Regional Institute of Mental Health
News | January 09, 2025

JP Nadda inaugurates new Library and Informatics Centre at LGB Regional Institute of Mental Health

He also laid the foundation stone for a state-of-the-art 50-bedded Critical Care Block (CCB)


Evonik partners with South Korean ST Pharm to increase its offerings for RNA and nucleic acid delivery
News | January 09, 2025

Evonik partners with South Korean ST Pharm to increase its offerings for RNA and nucleic acid delivery

Increases speed to market for drug developers working on nucleic acid therapeutics


Elinzanetant meets all primary and secondary endpoints in Phase III study OASIS 4 for treatment of vasomotor symptoms caused by breast cancer treatments
Diagnostic Center | January 09, 2025

Elinzanetant meets all primary and secondary endpoints in Phase III study OASIS 4 for treatment of vasomotor symptoms caused by breast cancer treatments

The study also met all secondary endpoints with a reduction in severity of VMS at weeks 4 and 12, a reduction in frequency of VMS at week 1 as well as improvements in sleep disturbances and menopause related quality of life


ProBioGen expands protein and viral manufacturing to drive continued growth
News | January 09, 2025

ProBioGen expands protein and viral manufacturing to drive continued growth

This strategic move aims to address the increasing global demand for biologics, enhancing ProBioGen's ability to support partners from cell line development t


Lilly to establish new global capability centre in Hyderabad
News | January 09, 2025

Lilly to establish new global capability centre in Hyderabad

Lilly plans to hire approximately more than 1,000 new highly-skilled team members


Sentynl Therapeutics receives USFDA acceptance and priority review of new drug application for CUTX-101 product candidate for treatment of Menkes disease
Drug Approval | January 07, 2025

Sentynl Therapeutics receives USFDA acceptance and priority review of new drug application for CUTX-101 product candidate for treatment of Menkes disease

Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A